3.40

4.29% 0.14

After Hours: 3.37 -0.03 -0.88%

Cabaletta Bio Inc (CABA)

Overview News Price History Option Chain Financials Why CABA Down? Discussions Forecast

Cabaletta Bio Inc stock is traded at $3.40, with a volume of 2.13M. It is up +4.29% in the last 24 hours and up +11.11% over the past month. Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.

Previous Close:

$3.26

Open:

$3.33

24h Volume:

2.13M

Relative Volume:

0.73

Market Cap:

$378.50M

Revenue:

Net Income/Loss:

$-167.86M

P/E Ratio:

-1.4825

EPS:

-2.2935

Net Cash Flow:

$-132.31M

1W Performance:

+10.03%

1M Performance:

+11.11%

6M Performance:

+17.24%

1Y Performance:

+203.57%

1-Day Range:

$3.29

$3.41

1-Week Range:

$3.04

$3.41

52-Week Range:

$1.06

$3.78

Cabaletta Bio Inc Stock (CABA) Company Profile

Name

Cabaletta Bio Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(267) 759-3100

Address

2929 ARCH STREET, PHILADELPHIA, PA

Employee

156

Twitter

@CabalettaBio

Next Earnings Date

2026-03-30

Latest SEC Filings

CABA's Discussions on Twitter

Compare CABA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CABA Cabaletta Bio Inc	3.40	362.91M	0	-167.86M	-132.31M	-2.2935
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-10-25	Resumed	Jefferies	Buy
Dec-20-24	Downgrade	Evercore ISI	Outperform → In-line
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Oct-10-24	Initiated	UBS	Buy
Feb-05-24	Initiated	Jefferies	Buy
Nov-29-23	Initiated	William Blair	Outperform
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-19-23	Initiated	Stifel	Buy
Sep-05-23	Initiated	Citigroup	Buy
Jul-18-23	Initiated	Guggenheim	Buy
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Aug-30-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Dec-08-21	Initiated	Wells Fargo	Overweight
Oct-19-21	Resumed	Morgan Stanley	Overweight
Jun-30-21	Initiated	Mizuho	Buy
Jan-08-21	Initiated	Chardan Capital Markets	Buy
Oct-13-20	Initiated	H.C. Wainwright	Buy
Nov-19-19	Initiated	Cowen	Outperform
Nov-19-19	Initiated	Evercore ISI	Outperform
Nov-19-19	Initiated	Morgan Stanley	Overweight

View All

Cabaletta Bio Inc Stock (CABA) Latest News

02:14 AM

Cellares’ Cell Shuttle used in first patient infusions of Cabaletta Bio CAR T therapy (CABA:NASDAQ) - Seeking Alpha

02:14 AM

12:41 PM

CABA: Cabaletta Bio Advances CAR T Cell Therapy with Cellares' Technology - GuruFocus

12:41 PM

Apr 14, 2026

Cabaletta Bio Doses First Patients With Rese-cel Manufactured on Cellares' Automated Platform - National Today

Apr 14, 2026

Patients dosed with Cabaletta’s rese-cel manufactured on Cellares’ Cell Shuttle - TipRanks

Apr 14, 2026

First patients dosed with Cabaletta Bio's rese-cel manufactured on Cellares' automated cell shuttle(TM) platform - marketscreener.com

Apr 14, 2026

First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform - The Joplin Globe

Apr 14, 2026

Cellares and Cabaletta Bio Successfully Infuse First Patients with Rese-cel - Intellectia AI

Apr 14, 2026

Apr 13, 2026

Cabaletta reports results, advances Rese-Cel autoimmune program - MSN

Apr 13, 2026

Aug Retail: What is Cabaletta Bio Incs P E ratio telling usLayoff News & Fast Exit and Entry Trade Guides - baoquankhu1.vn

Apr 13, 2026

Aug Wrap: Is Cabaletta Bio Inc stock trending bullishWeekly Stock Recap & Momentum Based Trading Ideas - baoquankhu1.vn

Apr 13, 2026

Apr 12, 2026

Cabaletta Bio (CABA) upgraded to buy: Here's what you should know - MSN

Apr 12, 2026

Apr 11, 2026

Institution Moves: Whats the MACD signal for Cabaletta Bio IncLong Setup & Weekly Watchlist for Hot Stocks - baoquankhu1.vn

Apr 11, 2026

Apr 09, 2026